AI-Powered Psychedelic Treatments: Special Status And Next-Gen Contests Winners
As psychedelics and AI travel their own development paths, here are some initiatives looking at ways of enhancing the former with the latter’s help.
MA, FL And OH Psychedelics Scientists And Educators’ Latest Research And Views
Along with a growing scientific corpus supporting the therapeutic potential of psychedelics, several states and most noticeably Massachusetts are seeing the decriminalization of natural substances via local measures.
Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More
Major Investor Commits $30 Million To Psychedelics Funding
Lucy Scientific Goes After Pasithea Therapeutics Common Shares For A ‘142% Premium’ Deal
Health Canada-licensed psychedelics producer Lucy Scientific Discovery (NASDAQ: LSDI) announced it has sent a proposal to biotech business Pasithea Therapeutics Corp.
Numinus’ Clinical Arm To Lead Enrollment Site For MindMed’s Phase 2b LSD Study
Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud
DMT’s Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous (IV) formulation of the company’s DMT compound, AP-188, aiming to treat both stroke and Traumati
Reunion Neuroscience Announces $13.1M Take-Private Transaction With Biotech Investment Firm
As of May 31, clinical-stage psychedelics company Reunion Neuroscience Inc.
Major Investor Commits $30M To Psychedelics Funding
Canadian psychedelics biotech Cybin Inc. (NYSE: CYBN) entered into a common share purchase agreement with institutional investor Lincoln Park Capital Fund (LPC) for the sale of up to $30 million (CA$41) of its common shares within a 36-month period.
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study
Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics committee and the Clinical Trials Registry to begin the world's first Phase 2a take-home LSD microdosing trial in patients with Major Depressive Disorder (MDD).
Mydecine’s Prospectus Supplement Closing Under Share Subscription And Management Update
Colorado-based next-generation psychedelics biotech Mydecine Innovations Group Inc. (OTC: MYCOF) announced that, in connection with its common share subscription agreement with a third-party investor dated this past March 10, it has filed a shelf prospectus supplement to its final base shelf prospectus for th